Share This Page
Litigation Details for medac Gesellschaft fur klinische Spezialpraparate mbH v. Somerset Therapeutics, LLC (D. Del. 2026)
✉ Email this page to a colleague
medac Gesellschaft fur klinische Spezialpraparate mbH v. Somerset Therapeutics, LLC (D. Del. 2026)
| Docket | 1:26-cv-00914 | Date Filed | 2026-07-24 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 35:1 Patent Infringement | Assigned To | Unassigned Judge |
| Jury Demand | None | Referred To | |
| Parties | SOMERSET THERAPEUTICS, LLC | ||
| Patents | 8,664,231 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in medac Gesellschaft fur klinische Spezialpraparate mbH v. Somerset Therapeutics, LLC
Details for medac Gesellschaft fur klinische Spezialpraparate mbH v. Somerset Therapeutics, LLC (D. Del. 2026)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2026-07-24 | External link to document | |||
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
Executive summary
- Case: medac Gesellschaft fur klinische Spezialpraparate mbH v. Somerset Therapeutics, LLC, No. 1:26-cv-00914 (filed 2026).
- Type of dispute: patent infringement and related IP claims tied to medac’s specialty pharmaceutical products (exact asserted patents and claim charts are required to complete a litigation merits analysis).
- Litigation posture: information needed to determine (i) asserted patent numbers, (ii) venue transfer or consolidation, (iii) Markman schedule, (iv) claim construction rulings, (v) preliminary injunction motions, (vi) pleadings stage status (complaint vs amended complaint), and (vii) any settlement or stipulations.
Litigation summary and analysis for medac Gesellschaft fur klinische Spezialpraparate mbH v. Somerset Therapeutics, LLC (1:26-cv-00914)
What claims did medac assert against Somerset in 1:26-cv-00914?
No case-accurate litigation summary can be produced without the complaint and each asserted-patent list (title, number, filing/priority, publication, issuance, and the specific infringement theories). A credible analysis requires the pleaded claims, product identifiers, and alleged infringement acts (manufacture, use, sale, offer for sale, importation).
Which patents were asserted?
- Asserted patent numbers and claims are not provided.
- Any attempt to name patents without record confirmation risks factual error.
What infringement theories were pleaded?
Common theories in Hatch-Waxman and related pharma IP suits include:
- direct infringement (making/using/selling/importing)
- induced infringement
- contributory infringement
- doctrine of equivalents
- infringement based on FDA labeling or product design
The operative pleadings are required to state which were actually used.
Where do the alleged accused products sit in the supply chain?
A litigation-grade summary must identify:
- the accused manufacturer(s) and seller(s)
- distribution entities
- whether the suit targets an NDA/ANDA/BLA filer or a generic/manufacturer channel
- whether the accused product is in final dosage form or bulk
No such facts are available in the provided prompt.
What is the procedural status of 1:26-cv-00914 (motions, scheduling, and hearings)?
A correct procedural timeline requires docket entries (ED tex, pacer docket, or court order text). Without them, the case posture cannot be stated.
Is the case at the complaint stage, claim construction, or trial?
- Claim construction (Markman), discovery, and pretrial conference schedules are not available from the prompt.
- Without docket data, any “at-this-stage” description would be speculative.
Were there any early motions?
Litigation analytics typically require whether the court ruled on:
- motion to dismiss (12(b)(6))
- motion for more definite statement
- transfer/venue
- stay pending PTO/ITC or parallel proceedings
- preliminary injunction or TRO
Those events are not provided.
Has any amended complaint been filed?
- Patent substitution, narrowing claims, or adding new asserted patents cannot be asserted without knowing docket amendments.
What patents protect medac’s product(s) that Somerset allegedly infringes?
A patent-estate analysis depends on:
- the exact asserted patents
- their expiration dates
- jurisdictional coverage
- prosecution history or terminal disclaimer data
- whether any patents are dependent on method-of-use, composition, device/administration, or manufacturing steps
None of that is included in the prompt.
How many patents are in medac’s asserted estate in this case?
Not determinable without the asserted-patent list.
What is the expected expiration and term posture?
Not determinable without:
- patent grant numbers
- filing/priority dates
- adjustments or disclaimers
- any patent term extension information
How strong is the patent estate in this litigation (validity and enforceability angles)?
A litigation-strength analysis normally covers:
- anticipation/obviousness art sets
- written description and enablement
- claim indefiniteness
- statutory subject matter (if applicable)
- inequitable conduct allegations
- ownership/standing challenges
- exhaustion or license defenses
The prompt provides no record-level data to evaluate those defenses or identify any invalidity arguments that Somerset pleaded.
What defenses is Somerset likely raising in 1:26-cv-00914?
A defensible answer requires Somerset’s answer, counterclaims, or motion papers. Common defenses in this case type include:
- non-infringement (no element-by-element correspondence)
- invalidity (anticipation/obviousness)
- unenforceability (inequitable conduct)
- lack of standing/ownership or improper plaintiff
- collateral estoppel or claim preclusion if parallel actions exist
No pleading text is provided, so defenses cannot be accurately assigned to Somerset.
How do claim construction issues drive outcomes in medac v. Somerset?
Claim construction is often outcome-determinative in pharma patent suits. A proper analysis requires:
- the disputed terms
- the parties’ proposed constructions
- the court’s final constructions (and dates)
- whether constructions narrowed or broadened the asserted claims
No construction orders are provided.
What court issued the case and what jurisdictional effects matter?
The case caption includes only the docket number. A litigation analysis typically needs:
- district and division
- judge assignment
- magistrate involvement
- local patent rules affecting disclosures and claim construction
- whether there are concurrent ITC or other district cases
The prompt does not include court or judge details.
What generic entry risks exist for Somerset products given this litigation?
A risk assessment requires:
- whether Somerset is launching a generic/biosimilar/authorized alternative
- whether an ANDA/BLA is involved and if it is Paragraph IV (or biosimilar 351(k) pathway)
- whether FDA approval timing aligns with patent expiry
- any stated launch date in pleadings or declarations
No FDA regulatory linkage is included.
Does this case involve Orange Book-listed patents or FDA regulatory exclusivities?
To analyze Orange Book status, you need:
- the specific NDA/ANDA numbers
- the Orange Book “patent” entries asserted
- listed exclusivity periods (NCE, pediatric, new method of use, etc.)
- whether patents are expiration-mapped and whether any are listed only for certain strengths or dosage forms
No NDA/ANDA data is provided.
Are there related actions (parallel suits, PTAB, ITC) impacting 1:26-cv-00914?
Parallel proceedings can change litigation posture via stay motions and issue preclusion. Required inputs include:
- whether any asserted patent is challenged at PTAB (IPR/PGR)
- whether ITC proceedings exist
- whether other district courts have rulings on the same patent set
No such data is provided.
What settlement or consent-judgment terms exist, if any, in 1:26-cv-00914?
Settlement posture is only verifiable through docket entries, stipulations, or court orders. The prompt includes no indication of:
- dismissal without prejudice or with prejudice
- covenant not to sue
- license agreement
- entry of consent judgment
- dismissed counts or redacted patent lists
No settlement terms can be summarized without record citations.
Key Takeaways
- A litigation-grade summary for medac Gesellschaft fur klinische Spezialpraparate mbH v. Somerset Therapeutics, LLC (1:26-cv-00914) cannot be completed from the information provided because no asserted-patent list, docket status, or court orders are included.
- To produce an outcome-oriented analysis, the record is required: complaint allegations (claims/patents), Somerset’s defenses, procedural posture orders, and any claim construction, injunction filings, PTAB/ITC links, and settlement entries.
FAQs
- What patents are asserted in medac v. Somerset Therapeutics, LLC (1:26-cv-00914)?
- What procedural stage is medac v. Somerset Therapeutics in, and what are the next scheduled deadlines?
- Is the accused product tied to an ANDA or 351(k) pathway in 1:26-cv-00914?
- Have any claim construction rulings been issued in the case?
- Did the parties settle or obtain a dismissal in 1:26-cv-00914?
References (APA)
- United States District Court docket for medac Gesellschaft fur klinische Spezialpraparate mbH v. Somerset Therapeutics, LLC, No. 1:26-cv-00914.
More… ↓
